Aurinia Pharmaceuticals Inc. Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used
Aurinia Pharmaceuticals Inc. (AUPH) reported Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used of $67.00 thousand for the 12-month period ending 2019-12-31, per its 40-F filed 2020-03-05.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed · last filed 2020-03-05
| Period end | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 12 month |
|---|---|---|
| 2019-12-31 | $67.00K 40-F · filed 2020-03-05 | |
| 2019-01-01 | $16.00K 40-F · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |